Gore Emily, Femino Christopher, Aronskyy Illya, Miller Alexander, Zelman Sara R, Winter Michael W, Dolinger Michael T
Department of Medicine, Icahn School of Medicine at Mount Sinai, The Mount Sinai Hospital, New York, NY, USA.
Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Dig Dis Sci. 2025 Sep 18. doi: 10.1007/s10620-025-09390-4.
Intestinal ultrasound (IUS) is a non-invasive, accurate tool for monitoring inflammatory bowel disease (IBD), with growing adoption in the United States for real-time disease management within treat-to-target algorithms. While international studies highlight strong patient support for IUS, U.S.-based data on patient preferences and engagement are limited.
This cross-sectional observational study, conducted at two academic IBD centers in the U.S., assessed patient experiences with IUS and preferences for disease monitoring.
Adults with Crohn's disease (CD) and ulcerative colitis (UC) seen for a routine visit were selected to undergo IUS-driven care or non-IUS-driven care, at the discretion of their provider. Participants then completed a 20-item survey, which included Likert scales for comparing disease-monitoring modalities, as well as measures of patient engagement (Patient Activation Measure (PAM-13), Morisky Medication Adherence Scale (MMAS-4)), and disease activity. Electronic health records were reviewed for clinical data.
Of 326 patients (209 (64.1%) with CD; 117 (35.9%) with UC), 219 (67.2%) were IUS exposed (underwent IUS-driven care on the date of survey or previously) and 107 (32.8%) were IUS naïve. 133 (60.7%) IUS-exposed participants expressed a strong preference for IUS when comparing disease-monitoring modalities, with 153 (69.9%) reporting no discomfort. 225/326 (69.0%) expressed the strongest confidence in colonoscopy. 101 (46.1%) IUS-exposed participants expressed stronger confidence in IUS vs. blood work (96; 43.8%), stool studies (78; 35.6%), and other cross-sectional imaging (79; 36.1%).
IUS is highly acceptable, well tolerated, and preferred by our U.S.
These findings support the implementation of IUS as a patient-centric monitoring tool.
肠道超声（IUS）是一种用于监测炎症性肠病（IBD）的非侵入性、准确工具，在美国越来越多地被用于基于治疗目标算法的实时疾病管理。虽然国际研究强调患者对IUS的大力支持，但美国关于患者偏好和参与度的数据有限。
这项横断面观察性研究在美国的两个学术性IBD中心进行，评估了患者对IUS的体验以及对疾病监测的偏好。
因常规就诊而被诊断为克罗恩病（CD）和溃疡性结肠炎（UC）的成年人，由其医生酌情选择接受IUS驱动的护理或非IUS驱动的护理。参与者随后完成了一项包含20个条目的调查，其中包括用于比较疾病监测方式的李克特量表，以及患者参与度测量（患者激活量表（PAM-13）、莫利斯基药物依从性量表（MMAS-4））和疾病活动度测量。对电子健康记录进行审查以获取临床数据。
在326名患者中（209名（64.1%）为CD患者；117名（35.9%）为UC患者），219名（67.2%）接受过IUS检查（在调查当日或之前接受过IUS驱动的护理），107名（32.8%）未接受过IUS检查。在比较疾病监测方式时，133名（60.7%）接受过IUS检查的参与者表示强烈偏好IUS，其中153名（69.9%）报告没有不适。225/326（69.0%）的参与者对结肠镜检查表现出最强的信心。101名（46.1%）接受过IUS检查的参与者对IUS的信心强于血液检查（96名；43.8%）、粪便检查（78名；35.6%）和其他横断面成像检查（79名；36.1%）。
IUS在美国人群中是高度可接受的，耐受性良好且更受青睐。这些发现支持将IUS作为一种以患者为中心的监测工具加以应用。
